<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436656</url>
  </required_header>
  <id_info>
    <org_study_id>CLGX818X2101</org_study_id>
    <secondary_id>C4221010</secondary_id>
    <secondary_id>2011-000556-42</secondary_id>
    <nct_id>NCT01436656</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma</brief_title>
  <official_title>A Phase I, Multicenter, Open-label, Dose-escalation Study of Oral LGX818 in Adult Patients With Locally Advanced or Metastatic BRAF Mutant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose&#xD;
      (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily&#xD;
      and/or every-other-day), a RAF kinase inhibitor. Patients with locally advanced or metastatic&#xD;
      melanoma harboring the BRAF V600 mutation (during dose escalation phase and expansion phase)&#xD;
      and patients with metastatic colorectal cancer harboring the BRAF V600 mutation (during the&#xD;
      expansion phase) will be enrolled. The study consists of a dose escalation part were cohorts&#xD;
      of patients will receive escalating oral doses of LGX818, followed by a safety dose expansion&#xD;
      part were patients will be treated with oral dose of LGX818 given at the MTD or RP2D.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 5, 2011</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Actual">October 1, 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities</measure>
    <time_frame>Approximately every 8 weeks (up to 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and nature of Adverse events and clinical activity</measure>
    <time_frame>Approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of LGX818</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>LGX818 Plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response per RECIST</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>This includes duration of response, time to response, progression free survival and overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline molecular status</measure>
    <time_frame>Approximately 3 years</time_frame>
    <description>Baseline molecular status (mutation/ amplification/ expression) in tumor tissue of potential predictive markers</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Melanoma and Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>LGX818 - Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LGX818 - Dose Expansion at MTD or RP2D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LGX818</intervention_name>
    <arm_group_label>LGX818 - Dose Expansion at MTD or RP2D</arm_group_label>
    <arm_group_label>LGX818 - Dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        For the dose escalation phase:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of locally advanced or metastatic melanoma (stage&#xD;
             IIIB to IV per American Joint Committee on Cancer [AJCC]). For the dose expansion&#xD;
             phase: (i) Histologically confirmed diagnosis of locally advanced or metastatic&#xD;
             melanoma (stage IIIB to IV per American Joint Committee on Cancer [AJCC]), or (ii)&#xD;
             confirmed diagnosis and non-resectable advanced metastatic colorectal cancer (mCRC)&#xD;
             for which no further effective standard therapy exists.&#xD;
&#xD;
          2. Written documentation of BRAF V600E mutation, or any other BRAF V600 mutation.&#xD;
&#xD;
          3. Evidence of measurable disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous therapy with a MEK inhibitor.&#xD;
&#xD;
          2. Symptomatic or untreated leptomeningeal disease.&#xD;
&#xD;
          3. Symptomatic or untreated brain metastasis.Patients previously treated for these&#xD;
             conditions that are asymptomatic in the absence of corticosteroid therapy are allowed&#xD;
             to enroll. Brain metastasis must be stable with verification by imaging.&#xD;
&#xD;
          4. Known acute or chronic pancreatitis.&#xD;
&#xD;
          5. Clinically significant cardiac disease&#xD;
&#xD;
          6. Impairment of gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of oral LGX818&#xD;
&#xD;
          7. Previous or concurrent malignancy. Exceptions to this exclusion criteria include:&#xD;
             adequately treated basal cell or squamous cell skin cancer; in situ carcinoma of the&#xD;
             cervix, treated curatively and without evidence of recurrence for at least 3 years&#xD;
             prior to study entry; or other solid tumor treated curatively, and without evidence of&#xD;
             recurrence for at least 3 years prior to study entry.&#xD;
&#xD;
          8. Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test (&gt; 5 mIU/mL).&#xD;
&#xD;
          9. History of thromboembolic or cerebrovascular events within the last 6 months&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>EDOG - Institut Claudius Regaud - PPDS</name>
      <address>
        <city>Toulouse</city>
        <state>Haute-garonne</state>
        <zip>31059 Cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Badalona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebrón - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro_CIOCC</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <state>Graubünden (DE)</state>
        <zip>07000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Japan</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Norway</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2011</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRAF mutant,</keyword>
  <keyword>BRAF mutated,</keyword>
  <keyword>melanoma,</keyword>
  <keyword>metastatic,</keyword>
  <keyword>advanced,</keyword>
  <keyword>RAF kinase inhibitor</keyword>
  <keyword>BRAF V600 mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

